Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Upwork Inc (UPWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Upwork Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Upwork Inc trades at $9.02 (market cap $1.12B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 7.2× Upwork Inc's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Upwork Inc nearer its low. Which is the better fit depends on your goals.
| BIO | UPWK | |
|---|---|---|
Market Cap | $8.04B | $1.12B |
Sector | Health | Industrials |
52-Week High | $339.75 | $22.11 |
52-Week Low | $241.71 | $7.84 |
Enterprise Value | $7.85B | $915.11M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
UPWK trades at $9.12, up 3.4% today, with a bullish technical signal from moving averages. The company reported $787.78M revenue and $115.43M net income for 2025, with strong profitability margins. Recent news highlights AI integration initiatives and board refreshment, but multiple law firms are investigating potential securities law violations following earnings misses and a guidance cut.
The outlook is mixed: analyst consensus is a Buy with a $10.67 price target, but earnings misses and legal scrutiny pose risks. Revenue growth has slowed, and net cash flow turned negative in 2025. Upside depends on successful AI adoption and execution, while downside risks include ongoing investigations and competitive pressures in the gig economy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →
